Pharmaceuticals
Pharmacy Distribution
from 1,754 today
Entero has rapidly established its presence in the fragmented pharmaceutical product distribution market in India, operating at a superior margin profile. We expect Entero to deliver a strong revenue/EBITDA/PAT CAGR over FY26-29E, and we initiate coverage with a BUY rating.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
